SAM domain and HD domain-containing protein 1 mRNA (SAMHD1 mRNA) (SAMHD1 mRNA)

SAM domain and HD domain-containing protein 1 (SAMHD1) mRNA is the transcript responsible for the synthesis of the SAMHD1 protein, a critical deoxynucleoside triphosphate triphosphohydrolase (dNTPase) [1]. The encoded protein maintains cellular dNTP homeostasis by catalyzing the hydrolysis of dNTPs into deoxynucleosides and inorganic triphosphate, thereby limiting the availability of substrates for DNA synthesis [1, 2]. This function makes SAMHD1 a potent restriction factor against retroviruses like HIV-1, as it starves the virus of the dNTPs required for reverse transcription [4]. In oncology, SAMHD1 mRNA expression is a key determinant of resistance to nucleoside analog chemotherapies, such as cytarabine, because the protein can dephosphorylate and inactivate the triphosphorylated forms of these drugs [2, 5]. Therapeutic targeting of SAMHD1 mRNA using antisense oligonucleotides or siRNA is being explored as a strategy to sensitize cancer cells to treatment by preventing the production of the resistance-conferring enzyme [5]. Furthermore, mutations in the SAMHD1 gene are associated with Aicardi-Goutières syndrome, an autoinflammatory disorder characterized by an inappropriate innate immune response to endogenous nucleic acids [3]. The mRNA itself serves as a biomarker for predicting patient response to certain leukemic treatments [2]. By modulating the levels of this transcript, researchers aim to overcome drug resistance and enhance the efficacy of existing nucleoside-based therapies [5].

Other names

SAM domain and HD domain-containing protein 1 transcriptMonocyte protein 5 mRNAMOP-5 mRNASAMHD1 transcript

Antisense inhibition or RNA interference to downregulate SAMHD1 protein expression, thereby preventing the enzymatic inactivation of nucleoside analog drugs and enhancing their cytotoxic activity.